目的 探討卡瑞利珠單抗聯(lián)合XELOX方案治療晚期結(jié)腸癌的臨床療效。方法 選取2021年1月-2023年1月京山市人民醫(yī)院收治的94例結(jié)腸癌患者,隨機(jī)分為對照組(47例)和治療組(47例)。對照組患者采用XELOX方案治療,第1天靜脈滴注注射用奧沙利鉑,130 mg/m²;第1~14天早、晚餐后口服卡培他濱片,1 000 mg/m²,2次/d。治療組在對照組基礎(chǔ)上靜脈滴注注射用卡瑞利珠單抗,200 mg/次,1次/3周,滴注2次。兩組患者均治療6周。觀察兩組患者臨床療效,比較治療前后兩組患者血清大腸特異性抗原-2(CCSA-2)、癌胚抗原(CEA)、糖類抗原19-9(CA19-9)、血管內(nèi)皮生長因子(VEGF-A)、VEGF受體2(VEGFR2)及生活質(zhì)量核心量表(QLQ-C30)評分。結(jié)果 治療后,治療組疾病控制率為80.85%,較對照組的61.70%明顯升高(P<0.05)。治療后,兩組患者血清CCSA-2、CEA、CA19-9、VEGF-A、VEGFR2水平均較治療前明顯降低(P<0.05),且治療組較對照組下降更顯著(P<0.05)。治療后,兩組患者QLQ-C30評分均較治療前明顯升高(P<0.05),且治療組較對照組升高更顯著(P<0.05)。結(jié)論 卡瑞利珠單抗聯(lián)合XELOX方案可有效改善晚期結(jié)腸癌患者血清中異常腫瘤標(biāo)志物及VEGF-A、VEGFR2等血管生長因子水平,提高生活質(zhì)量,療效顯著。

Objective To explore the clinical efficacy of camrelizumab combined with XELOX regimen in treatment of advanced colon cancer. Methods Patients (94 cases) with advanced colon cancer in People's Hospital of Jingshan from January 2021 to January 2023 were randomly divided into control (47 cases) and treatment (47 cases) group. Patients in the control group were administered with XELOX regimen, Oxaliplatin for injection was given intravenously on 1 d, 130 mg/m²; Capecitabine Tablets were taken orally after breakfast and dinner on 1-14 d, 1 000 mg/m², twice daily. Patients in the treatment group were iv administered with Camrelizumab for injection on the basis of the control group, 200 mg/time, once every 3 weeks. Patients in two groups were treated for 6 weeks. After treatment, the clinical evaluations were evaluated, the levels of serum CCSA-2, CEA, CA19-9, VEGF-A and VEGFR2, and the QLQ-C30 scores in two groups before and after treatment were compared. Results After treatment, the disease control rate of the treatment group was 80.85%, which was significantly higher than that of the control group (61.70%, P < 0.05). After treatment, the serum levels of CCSA-2, CEA, CA19-9, VEGF-An and VEGFR2 in two groups were significantly lower than those before treatment (P < 0.05), and the decrease in the treatment group was more significant than that in the control group (P < 0.05). After treatment, QLQ-C30 scores in two groups were significantly higher than those before treatment (P < 0.05), and the level in the treatment group was significantly higher than that in the control group (P < 0.05). Conclusion Camrelizumab combined with XELOX regimen can effectively improve the serum levels of abnormal tumor markers and vascular growth factors such as VEGF-An and VEGFR2 in patients with advanced colon cancer, and improve the quality of life.

R979.1

湖北省衛(wèi)生健康委科研項目（WJ2021F119）